Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
A highly respectable response rate with the company’s oncolytic virus bodes well in the post-checkpoint inhibitor setting.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Replimune plans to test its oncolytic viruses in tumours that have spread to the liver, but an early look at Opdivo combo data fails to impress.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.